Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Central banks announce dollar liquidity measures to ease banking crisis
    • Xi Jinping to test limits of friendship with Vladimir Putin on Russia state visit
    • South African military deployed to prevent planned national shutdown
    • Two companies, one trade: the switch that keeps Putin’s oil flowing
    • Wirecard fraudster Jan Marsalek’s grandfather was suspected Russian spy
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • UBS agrees $3.25bn rescue deal for rival Credit Suisse
      • Wall Street CEOs try to come up with new plan for First Republic
      • UBS agrees to buy Credit Suisse for more than $2bn
      • Swiss under fire for shotgun marriage of Credit Suisse and UBS
      • Rupert Murdoch engaged to be married for fifth time
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Banks and markets updates from March 20: S&P cuts UBS’s outlook, Credit Suisse warns of possible job cuts
      • Holders of $17bn of Credit Suisse bonds wiped out under UBS takeover
      • US bank stocks rise as investors assess efforts to calm turmoil
      • Credit Suisse bondholders in uproar over $17bn debt wipeout
      • Central banks announce dollar liquidity measures to ease banking crisis
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The real meaning of Xi’s visit to Putin
      • There are several reasons to worry about the health of Europe’s banks
      • Banking turmoil intensifies the need for better Federal Reserve policymaking
      • Fall of Credit Suisse shows more work is needed on bank risk
      • Global banking is now inside Schrödinger’s box
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • From SVB to the BBC: why did no one see the crisis coming?
      • Football’s first female super-agent Rafaela Pimenta on dealmaking and discrimination
      • Social media content moderators lead charge for better rights
      • Patrick Vieira on making the switch to management: ‘It’s much easier to play football’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Meet the watch influencers
      • Five great Greek boltholes to book 
      • Michael Heseltine: ‘The adults are back in charge’
      • How Putin’s war destroyed a golden age of Russian culture
      • When Hong Kong stood still
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Biogen Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Thursday, 29 December, 2022
      Congress faults US regulator’s approval of Biogen Alzheimer’s drug

      Committees cite inappropriate collaboration between FDA and drugmaker

    • Friday, 2 December, 2022
      The editorial board
      A glimmer of hope in treating Alzheimer’s disease

      Dementia drug development, diagnostics and delivery still require much more investment

    • Tuesday, 29 November, 2022
      Eisai Co Ltd
      Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

      Shares fall 11% following two patient deaths in trials of lecanemab

    • Monday, 28 November, 2022
      LexDrugs research
      Dementia/Biogen: causal controversy means investors must take a stance Premium content

      The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

    • Wednesday, 28 September, 2022
      Pharmaceuticals sector
      Biogen and Eisai shares surge after Alzheimer’s drug trial success

      Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

    • Friday, 23 September, 2022
      Health sector
      Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

      Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

    • Wednesday, 21 September, 2022
      Pharmaceuticals sector
      Biogen drug slows progress of motor neurone disease in landmark trial

      Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis

    • Wednesday, 4 May, 2022
      FT News Briefing podcast8 min listen
      Draghi urges EU to abandon unanimity requirement

      Biogen chief to step down after the company’s Alzheimer’s drug flops

    • Tuesday, 3 May, 2022
      Biogen chief to step down after Alzheimer’s drug flops

      US biotech to dismantle sales infrastructure for treatment as it begins search for successor

    • Sunday, 17 April, 2022
      Anjana Ahuja
      Hasty approval for Alzheimer’s drug offers a cautionary tale

      FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

    • Monday, 20 December, 2021
      Biogen halves price of Alzheimer’s drug after sales fall short

      Insurers’ reluctance to pay for Aduhelm treatment forces biotech to lower costs as EMA highlights safety concerns

    • Wednesday, 17 November, 2021
      European regulators cast doubt on Biogen Alzheimer’s drug

      Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment

    • Wednesday, 20 October, 2021
      Biogen sells just $300,000 worth of contentious Alzheimer’s drug

      Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

    • Thursday, 22 July, 2021
      Biogen defends contentious $56,000 Alzheimer’s drug

      Pharma group blames ‘misinformation’ for overshadowing approval of therapy

    • Friday, 9 July, 2021
      US Food & Drug Administration
      FDA calls for probe of staff involved in divisive Alzheimer’s approval

      US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment

    • Monday, 5 July, 2021
      News in-depthPharmaceuticals sector
      Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

      Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

    • Wednesday, 16 June, 2021
      Pharmaceuticals sector
      Biogen’s Japanese partner calls for global action on Alzheimer’s

      Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

    • Friday, 11 June, 2021
      The Big Read
      The Alzheimer’s economy: is the new $56,000-a-year drug worth it?

      US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high

    • Tuesday, 8 June, 2021
      The FT ViewThe editorial board
      How to make the most of the Alzheimer’s drug approval

      FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line

    • Tuesday, 8 June, 2021
      Lex
      Biogen/Alzheimer’s: the high cost of hope Premium content

      Lofty prices reward risky, expensive research. But aducanumab’s pricing will raise eyebrows

    • Tuesday, 8 June, 2021
      Drug prices
      Biogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costs

      Campaigners hit out at high price for controversial treatment that has divided scientists

    • Monday, 7 June, 2021
      Pharmaceuticals sector
      Alzheimer’s drug from Biogen wins US approval

      FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy

    • Monday, 7 June, 2021
      Q&ADrugs research
      Alzheimer’s sufferers await ruling on potential blockbuster drug

      Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA

    • Friday, 6 November, 2020
      Biogen Alzheimer’s drug in doubt after criticism from expert panel

      Scientists express scepticism of trial data and US regulatory process at fiery hearing

    • Wednesday, 4 November, 2020
      Biogen shares leap after ‘substantial evidence’ Alzheimer’s drug is effective

      FDA staff give positive clinical review to what could be first new treatment in US for decades

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In